{"id":506477,"date":"2020-09-11T17:24:01","date_gmt":"2020-09-11T17:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=506477"},"modified":"2020-09-11T17:24:01","modified_gmt":"2020-09-11T17:24:01","slug":"immune-thrombocytopenia-itp-pipeline-insight-2020-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/immune-thrombocytopenia-itp-pipeline-insight-2020-by-delveinsight_506477.html","title":{"rendered":"Immune Thrombocytopenia (ITP) Pipeline Insight, 2020 by DelveInsight"},"content":{"rendered":"
\"Immune<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Immune thrombocytopenia (ITP) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Immune thrombocytopenia (ITP) market. A detailed picture of the Immune thrombocytopenia (ITP) pipeline landscape is provided, which includes the disease overview and Immune thrombocytopenia (ITP) treatment guidelines. <\/div>\n

“Immune thrombocytopenia (ITP) Pipeline Insight, 2020<\/strong><\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Immune thrombocytopenia (ITP) <\/strong>market. A detailed picture of the Immune thrombocytopenia (ITP) <\/strong>pipeline landscape is provided, which includes the disease overview and Immune thrombocytopenia (ITP) <\/strong>treatment guidelines.<\/p>\n

Immune Thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of ITP stem from a low platelet count leading to excessive bleeding. In severe cases, frequent bleeding episodes may result in low levels of circulating red blood cells (anemia), which may cause fatigue and impair response to exertion. In rare cases, serious bleeding into the brain (intracranial hemorrhage) may occur.<\/p>\n

View report: https:\/\/www.delveinsight.com\/sample-request\/immune-thrombocytopenia-itp-pipeline-insight<\/a><\/strong><\/p>\n

The assessment part of the report embraces in-depth Immune thrombocytopenia (ITP) <\/strong>commercial assessment and clinical assessment of the Immune thrombocytopenia (ITP) <\/strong>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune thrombocytopenia (ITP) <\/strong>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Immune thrombocytopenia (ITP) of <\/strong>pipeline development activities<\/p>\n

The report provides insights into:<\/p>\n